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Abstract  1 
 2 
Background: Patients with Alzheimer‟s disease (AD) who deteriorate rapidly are likely to 3 
have a poorer prognosis. There is a clear need for a clinical assessment tool to detect such a 4 
decline in newly diagnosed patients. 5 
Objective: To identify the predictive factors of rapid cognitive decline (RCD) in a cohort of 6 
patients with mild to moderate AD ; and to validate a self-questionnaire for caregivers as a 7 
diagnostic tool for rapid decline. 8 
Design and analysis: an open-label, observational, 12-month, multicenter, French study. 9 
Physicians were asked to record data of three eligible rivastigmine naïve (or on rivastigmine 10 
for < 1 year) AD patients. Risk factors of RCD and the detection power of the Détérioration 11 
Cognitive Observée scale (Deco), a 19 item self-questionnaire for caregivers, were assessed at 12 
endpoint using regression analyses. 13 
Results: Out of the 361 patients enrolled in the study, 91 (25.2%) were excluded due to loss of 14 
follow-up. Among subjects using cholinesterase inhibitors or memantine, 161 (59.6%) 15 
experienced a stabilization (29.2%) or an improvement (30.4%) in global functioning as 16 
measured by the CGI-C. Sixty of the remaining 204 patients retained for analysis (29.6%, CI 17 
95% [23.4; 35.8]) lost three or more points on the MMSE score between the inclusion and one 18 
of the follow-up visit. In the multivariate logistic regression analysis, institutionalization, 19 
higher level of education and the loss of 3 points or more on the MMSE were found to be 20 
significant predictors of a rapid cognitive loss in this population. The threshold which 21 
maximizes the predictive values of the Deco score as a diagnostic tool of rapid cognitive 22 
decline was significantly different according to the age of the patient (below or over 75 years 23 
old). A score below 16 for patients < 75 years old and below 14 for patients  ≥ 75 years old 24 
consistently predicted a RCD within the next year. 25 
Conclusion: The Deco test appears to be a simple tool to alert the physician to the possibility 26 
of an aggressive course of the disease which warrants particular management. 27 
 28 
Key words: Alzheimer’s disease, rapid cognitive decline, diagnostic tool29 
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INTRODUCTION 1 
Neurodegenerative dementias such as Alzheimer Disease (AD) are characterized by a 2 
progressive cognitive decline. However, the rate of progression can be highly variable from 3 
one patient to another [1] and some patients could have a more rapid cognitive decline (RCD). 4 
These patients are likely to have a poorer prognosis, with a higher mortality rate or a lower 5 
survival rate without severe dementia, than those with slower progression rates [1-3].   6 
  A prospective observational study performed in a population of 455 AD patients 7 
followed for at least one year, demonstrated that the risk of deterioration was significantly 8 
decreased in patients taking cholinesterase inhibitors (ChEIs) for at least one year compared 9 
to untreated patients [4]. To date, rivastigmine is the only drug which has been specifically 10 
studied in patients with RCD. A meta-analysis of four 6-month, double-blind, placebo-11 
controlled phase studies [5] showed that patients who experienced rapid decline, i.e. a decline 12 
of at least 4 points of the ADAS-cog score, during 26 weeks of placebo treatment, improved 13 
significantly more after 12 weeks of rivastigmine therapy than those who had declined by less 14 
than 4 points in the first 26 weeks. Thus, identifying AD patients at risk of RCD is important 15 
as these patients might benefit from specific primary or secondary care including more 16 
frequent clinical and neuropsychological evaluations, more frequent adaptation of drug 17 
treatment and more effective support for the caregiver. 18 
Several factors may predict RCD in AD patients:  cognitive status, presence of Extra-19 
Pyramidal Signs, psychotic symptoms and hallucinations, prominent sub-cortical pathology 20 
with attention and executive deficits and poor nutrition [6; 7]. However many of these factors 21 
are of limited interest in a clinical setting for individual patients as it is difficult to obtain 22 
valid information about most of them during the time of a consultation. There is thus a clear 23 
need for a simple clinical assessment tool, drawing on caregiver input, to detect RCD in 24 
recently diagnosed patients. The “Détérioration Cognitive Observée” (Deco) scale is a 19-item 25 
questionnaire administered to a person with at least a monthly contact with the patient. Its aim 26 
is to evaluate the change in cognitive functioning of the patient over the previous year. This 27 
instrument has been shown to be highly sensitive to early changes in cognitive functioning in 28 
previous studies [8]. 29 
The objectives of the prospective study we report here were  to identify the predictive factors 30 
of RCD in a cohort of patients with mild to moderate AD ; and to analyze the predictive value 31 
of a self-questionnaire for caregivers (the Deco score) as a simple diagnostic tool for RCD. 32 
 33 
 34 
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PATIENTS AND METHODS 1 
Study Design 2 
EXPLORE was an open label, observational cohort study, 12-month, multicenter, 3 
French study for which 350 neurologists, geriatricians and psychiatrists were contacted in 4 
order to finally include 250 of them. Each was asked to record data of three eligible patients. 5 
Eligibility criteria included: outpatients with AD over fifty years old, satisfying the criteria of 6 
the fourth edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) for 7 
dementia and those of NINCDS-ADRDA Work Group; with Mini-Mental State Examination 8 
(MMSE) [9] scores between 10 and 26; initiating therapy for the first time with rivastigmine 9 
or having already received rivastigmine for less than one year; with a planned follow-up visit 10 
within 12 months of enrolment and a caregiver‟s burden assessment; with an available 11 
informant. Patients not treated according to the product labeling, patients involved in a 12 
clinical trial or patients treated by an experimental drug within the previous 4 weeks were 13 
excluded. Investigators were advised to follow product labeling. 14 
The Steering Committee, the French National Council of Medical Practitioners Order (CNO) 15 
and the National Council of Informatics and Freedom (CNIL) approved the study. All the 16 
patients were given a study information sheet. 17 
For the present analysis, only subjects followed during twelve months were considered 18 
(n=204). Figure 1 is a detailed flow chart of patients „selection and exclusion. 19 
 20 
Study assessments 21 
At study entry, a detailed medical history of each patient was taken and baseline and 22 
follow-up assessments of cognitive performances was performed. 23 
Rapid cognitive decline was defined as a decline of at least three points of MMSE during the 24 
one year of follow-up. The following potential predictive factors of RCD were collected at 25 
baseline: MMSE, presence of behavioral disorders reported by the patient or his family 26 
(delusions, hallucinations, agitation/aggression), presence of extrapyramidal signs, lack of 27 
autonomy for the key Instrumental Activities of Daily Living (IADL) items (budget, phone, 28 
drugs, transport) [10], lack of stabilization with previous IChE or memantine treatment, Body 29 
Mass Index (BMI) and level of education. The clock drawing test[11], the 5-word test[12] and 30 
a verbal fluency test were also taken into account. 31 
The 19-item caregiver questionnaire, the Deco score was collected at the end of the 12-32 
month follow-up.   33 
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 Safety (vital signs, adverse events and a physical examination) regarding the use of 1 
IChE was assessed throughout the study as needed. 2 
 3 
Data analysis 4 
Characteristics of the patients who were seen at the12-month visit were compared to 5 
those of all subjects enrolled in the study by appropriate univariate statistical tests. 6 
Using simple and multiple logistic regressions, we studied the risk of RCD according to 7 
baseline characteristics of the patients. The multivariate analysis included all variables 8 
significantly associated with the risk in the univariate analysis at a p-value < 0.10. Moreover, 9 
we compared mean values of the Deco score according to some baseline characteristics of the 10 
patients. We used student t-test for the comparison. 11 
In addition, we ran a Receiver Operating Characteristic (ROC) analysis to detect the best 12 
threshold of diagnosis of RCD for the Deco score. Sensitivity, specificity, positive and 13 
negative predictive values were calculated for the best thresholds found from the observed 14 
ROC curve. We systematically sought for interactions between age and Deco score on the risk 15 
of RCD. Indeed, the risk of rapid decline is higher among younger subjects so we 16 
hypothesized that the predictive value of Deco might have a differential association with RCD 17 
according to age. SAS statistical software version 9.2 was used to perform analyses. 18 
 19 
 20 
RESULTS 21 
Patients 22 
 Three hundred and sixty one patients were enrolled in the study by 152 neurologists, 23 
geriatricians and psychiatrists. Among subjects using ChEI or memantine, 161 patients 24 
(59.6%) experienced a stabilization (29.2%) or an improvement (30.4%) in global 25 
functioning, as measured by the CGI-C. One hundred and fifty seven patients (25.2%) were 26 
excluded from analysis because of loss of follow-up between baseline and the 12-month 27 
follow-up (n=151) or missing value on MMSE (n=6) (figure 1). Baseline characteristics of the 28 
analyzed and enrolled populations were comparable (Table 1). In the analyzed population, 89 29 
patients (43.6%) had received prior ChEI treatment and 115 (56.4%) were de novo patients. 30 
Of the 89 patients who had received prior ChEI treatment, 63 patients were already treated by 31 
rivastigmine and 26 discontinued from a previous treatment by another ChEI. 32 
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There were more women than men (58.3% versus 41.7%) and the mean age was 1 
approximately 78 years (range 51-102 years). At baseline, patients included in this analysis 2 
had a mean MMSE score of 19.7 ± 4.4. 3 
For patients who had been previously treated by ChEIs, the mean duration of treatment before 4 
starting the study was 14.0 ±  14.3 months with a mean MMSE decrease of 2.1 ± 3.0 (- 1.1 ± 5 
2.6 for rivastigmine; - 4.1 ± 2.8 for donepezil and -3.6 ± 3.0 for galantamine). 6 
For the analyzed population, the MMSE decrease within the previous year was only known 7 
for 101 patients (i.e., data missing for 103).  8 
The mean follow-up period was 377.6 (± 61.2) days.  9 
 10 
Predictive factors of cognitive decline 11 
Sixty of the 204 patients retained for analysis (29.4%, 95%CI [23.4; 35.8]) were 12 
qualified as rapid cognitive decliners as they lost three or more points on the MMSE score 13 
between the inclusion and the 12-month follow-up visit.  14 
  Table 2 shows that the demographic and neuropsychological characteristics 15 
significantly associated with RCD by univariate analysis are: living in an institution and a 16 
high level of education (p-value < 0.03). In addition, a weaker level of autonomy and the loss 17 
of 3 points or more on the MMSE during the year prior to inclusion tended to be associated 18 
with RCD (p-value < 0.07). As there was a high number of missing values for the variable 19 
“loss of 3 points or more on the MMSE during the year prior inclusion”, two multivariate 20 
models were performed to analyze the risk of RCD (table 3). Model 1 included residential 21 
status, level of education and loss of autonomy. In this model, only the level of education 22 
remained significantly associated with RCD (OR = 2.21, 95%I.C. (1.12 – 4.37)). The second 23 
model (model 2) was further adjusted for the loss of more than 3 points on MMSE prior 24 
inclusion. In this model, the level of education and the loss of more than 3 points on MMSE 25 
were significant predictors of rapid decline. 26 
 27 
The Deco questionnaire 28 
The mean Deco questionnaire score was 19.0 ± 8.8. It was significantly different 29 
between rapid decliners (15.5 [13.6; 17.5]) and slow decliners (20.3 [18.8; 21.8]) (p for 30 
difference = 0.001) (table 4). 31 
Table 4 displays the mean of the Deco score according to baseline characteristics of 32 
the patients. No significant association was found for socio-demographic characteristics. 33 
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Significant lower values of Deco scores were observed for subjects with low level of (p-value 1 
= 0.07). 2 
Figure 2 shows the ROC curve of the predictive value of RCD according to the Deco 3 
score. Visually, the threshold which maximizes the specificity and the sensitivity of the score 4 
seems to be between 16 and 18. Table 5 reports the risks of RCD as well as the results from a 5 
sensitivity/specificity analysis for three thresholds (a Deco score <= 16, <=17 or <=18). The 6 
best model in terms of risk was observed for the threshold of 16. The risk of RCD for a 7 
patient having a score <= 16 for the Deco questionnaire was three times higher than for a 8 
patient scoring over 16 (p=0.002). However, we found an interaction between age and the 9 
threshold of 16 on the risk of RCD. For this threshold, the risk of RCD was significantly 10 
increased among younger subjects (age < 75) but not among older ones (respectively OR = 11 
6.7, 95%C.I. (1.8-25.1) and OR = 2.1, 95%C.I. (0.9-4.8)). As a consequence we ran new 12 
analyses to evaluate the best predictive thresholds of RCD according to age-group (below or 13 
over 75). Results are reported in table 6. We found that a threshold of 16 among subjects aged 14 
below 75 years old and a threshold of 14 for subjects older than 75 years old maximized the 15 
predictive values of the Deco score. Sensitivity, specificity and predictive values were 16 
consistently better than in the analysis pooling the two age-groups. 17 
 18 
DISCUSSION 19 
In this one year observational study we found that 29.4% of patients with AD lost 3 20 
points or more at the MMSE score and were thus classified as rapid decliners over the study 21 
period. Living in an institution, having a high educational level and being impaired for at least 22 
two activities in daily living were significantly associated with RCD. Finally, the Deco score 23 
was differently related to the occurrence of RCD according to the age of the patient. A 24 
threshold of 16 was found to be the best diagnostic tool for RCD among subjects aged < 75 25 
years old while a threshold of 14 was found for subjects aged ≥ 75 years old. 26 
In our study we found a relatively low proportion of rapid decliners compared with 27 
other studies. Although other definitions of cognitive decline have been proposed [3; 13], a 28 
decline of 3 points or more of the Mini-Mental State Examination (MMSE) over one year is a 29 
commonly used definition of RCD. Indeed, several clinical or population-based studies have 30 
shown that this threshold of decline was strongly linked to mortality or entry in an institution 31 
[2; 14]. Moreover, the use of MMSE compared to other neuropsychological tests is the only 32 
one to fit with clinical practice. In addition, all our patients were using ChEI so the low 33 
7 
 
proportion of rapid decliners found is consistent with the fact that rivastigmine, which is the 1 
only therapy studied in this population, has been shown to reduce the risk of rapid cognitive 2 
decline in patients using ChEI [4; 15].  3 
 As AD patients with RCD have a poorer prognosis, they warrant particular attention 4 
from the clinician. Previous efforts have been made to identify risk factors of rapid decline 5 
which could be targeted for timely introduction of preventive actions [6; 7; 16; 17] . In our 6 
study, demographic factors as living in institution and high level of education, and previous 7 
rapid decline appear as independent factors correlated with a rapid disease progression, while 8 
the usual clinical predictors as poor nutritional status, psychotic or extrapyramidal signs were 9 
not found to be correlated. While this lack of correlation could be attributed to the greater 10 
benefits of rivastigmine in this population [5; 7], the low proportion of patients in our study 11 
with such clinical symptoms at baseline should also be taken into account. 12 
Even if certain factors may be good predictors of rapid decline, available data remain 13 
contradictory [18] and are not sufficient or relevant in routine practice for clinical-decision 14 
making, especially for newly diagnosed patients.  In this respect, we aimed to assess the 15 
capacity of a new scale to evaluate the one-year change in cognitive functioning of patients 16 
according to their caregiver (or a person in contact with them). The Deco questionnaire used 17 
in this study appeared to be a valuable clinical tool for the detection of RCD. Indeed, when 18 
taking into account the age of the patients, thresholds of detection were strongly associated 19 
with RCD. A Deco score of less than 16 among patients under 75 years old, and of less than 20 
14 among patients over 75 years old, was found to be strongly associated with RCD. The risk 21 
of being a rapid decliner was 3 to 6 times higher among patients whose caregiver scored less 22 
than the threshold found for the Deco score. Moreover, the positive predictive value was close 23 
to 50% in the younger age-group which is a relevant value for clinical decision making. 24 
Indeed, it indicates that if an informant reports a score lower than 16 for a patient, there is 25 
50% chance that this subject has actually encountered a rapid decline within the previous 26 
year. Preventive care for these subjects appears necessary and will be useful for one patient 27 
out of 2. In addition, it is to be noted that the predictive values of the Deco score were better 28 
in the younger group of patients. This finding may be explained by the fact that older patients 29 
complain less than younger ones and they, as well as their caregivers, may attribute their 30 
changes in cognitive performances to age rather than to a pathological process. They may 31 
report less frequently little cognitive changes. Hence, the Deco questionnaire could represent 32 
a simple way of detecting patients with a high probability of rapidly progressing symptoms 33 
and thus to adapt disease management accordingly. 34 
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While our results are promising, this study does have some limitations. It remains 1 
merely a historical comparison and no definitive conclusion can be drawn. Moreover, only a 2 
low number of neurologists finally recruited patients. Together with the fact that a quarter of 3 
the patients were lost to follow-up, this could have introduced a bias. Our sample may not be 4 
fully representative of the AD population and thus our results should be interpreted with 5 
caution. Nonetheless, when enrolled patients‟ baseline characteristics were compared to those 6 
of the finally analyzed population, no difference was found, especially in the items of level of 7 
autonomy and cognitive impairment. 8 
Overall this study suggests that AD patients at risk of RCD can be identified in the 9 
setting of a regular consultation by means of the Deco questionnaire. Once alerted to the 10 
possibility of an aggressive disease course, the physician could pay particular attention to 11 
these patients and adapt disease management accordingly. 12 
13 
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Table 1 – Comparison of baseline characteristics of enrolled and analyzed patients 1 
 2 
 Enrolled Population 
N = 361 
Analyzed population 
N = 204 
Age (years), m ± SD 77.9 ± 7.55 78.0 ± 7.5 
Sex (female) 215 (59.6%) 119 (58.3%) 
Level of education 
  * long secondary school 
 
92 (25.6%) 
 
53 (26.0%) 
Residential status (out-patients) 302 (83.7%) 169 (82.8%) 
Duration of the disease (years) , m ± SD 1.8 ± 1.5 1.8 ± 1.4 
Psychotropic drugs 
  * neuroleptics 
  * antidépressive drugs 
170 (47.1%) 
31 (8.6%) 
98 (27.1%) 
106 (52.0%) 
20 (9.8%) 
60 (29.4%) 
Previous treatment by ChEI  
 * none 
 * rivastigmine 
 * other ChEI 
 
214 (59.3%) 
97   (26.9%) 
50   (13.8%) 
 
115 (56.4%) 
63 (30.9%) 
26 (12.7%) 
Memantine 26   (7.2%) 10 ( 4.9%) 
MMSE score, m ± SD 19.6 ± 4.6 19.7 ± 4.4 
mini-Zarit score, m ± SD 3.1 ± 1.7 3.1 ± 1.7 
4-IADL score (≥ 2 activities) 225 (62.4%) 123 (60.3%) 
5 words test , m ± SD 5.6 ± 2.3 5.7 ± 2.3 
Verbal fluency, m ± SD 10.7 ± 5.5 10.5 ± 5.1 
Figures are given as n and % unless otherwise specified 3 
SD: Standard Deviation4 
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Table 2. Association between baseline characteristics of patients and the risk of rapid 1 
cognitive decline. Univariate logistic regression. 2 
    
Rapid cognitive 
decline     
    
Yes 
n=60 
No 
n=144 OR (95%I.C.) p-value 
Sex     
 Male 25 (29.4) 60 (29.4)   
 Female 35 (70.6) 84 (70.6) n.a  
Age     
 <75 years old 16 (26.7) 43 (29.9)    1.00  
 >= 75 years old 44 (73.3) 101 (70.1) 1.17 (0.60-2.30) 0.647 
Residential status     
 Out-patients 44 (73.3) 125 (86.8)    1.00  
 Institution 16 (26.7) 19 (13.2) 2.39 (1.13-5.06) 0.022 
Level of education     
 primary or short secondary school 22 (36.7) 31 (21.5)    1.00  
 long secondary school  38 (63.3) 113 (78.5) 2.11 (1.09-4.08) 0.026 
BMI     
 < 18.5 kg/m² 9 (23.1) 30 (20.8)    0.68 (0.26-1.78) 0.432 
 18 <= BMI < 25   kg/m² 15 (30.6) 34 (23.6)    1.00  
 >= 25  kg/m² 36 (60.0) 80 (55.6) 1.02 (0.50-2.10) 0.957 
MMSE     
 >=20 35 (58.3) 78 (34.2)    1.00  
 <20 25 (41.7) 66 (45.8) 0.84 (0.46-1.55) 0.586 
Verbal fluency     
 >=15 12 (20.3) 27 (18.9)    1.00  
 <15 47 (79.7) 116 (81.1) 0.91 (0.43-1.95) 0.811 
5 words     
 >=8 10 (16.7) 36 (25.2)    1.00  
 <8 50 (83.3) 107 (74.8) 1.68 (0.77-3.66) 0.190 
Clock     
 >2 22 (37.9) 48 (35.6)    1.00  
 <=2 36 (62.1) 95 (66.4) 0.83 (0.44-1.56) 0.557 
Symptoms     
 Agitation 13 (21.7) 22 (15.3) 1.72 (0.76-3.93)* 0.194 
 Hallucination 9 (15.0) 16 (11.1) 1.64 (0.65-4.18)* 0.298 
 Strolling 6 (10.0) 13 (9.0) 1.35 (0.46-3.92)* 0.584 
 Depression 14 (23.3) 38 (26.4) 1.08 (0.50-2.31)* 0.851 
 EPS 6 (10.0) 18 (12.5) 0.97 (0.35-2.73)* 0.959 
Loss of autonomy for at least 2 activities   
 No 18 (30.0) 63 (43.8) 1.00  
 Yes 42 (70.0) 81 (56.2) 1.81 (0.95-3.45) 0.069 
Previous ChEI treatment   
 No 32 (53.3) 83 (57.6) 1.00  
 Yes 28 (46.7) 61 (42.4) 1.19 (0.65-2.18) 0.572 
Loss  >= 3 points on MMSE in the previous year  
 No 10 (29.4) 33 (49.3) 1.00  
  Yes 24 (70.6) 34 (50.8) 2.33 (0.97-5.61) 0.060 
* Compared with none trouble    
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Table 3. Risk of rapid decline in two multivariate logistic regression analyses 
    Model 1 (n = 204)   Model 2 (n = 101) 
    OR (95%I.C.) p-value   OR (95%I.C.) p-value 
Residential status           
 Out-patients 1.00   1.00  
 Institution 1.95 (0.89 - 4.31) 0.097  2.88 (0.97 - 8.59) 0.057 
Level of education      
 Primary or short secondary school 1.00   1.00  
 long secondary school 2.21 (1.12 - 4.37) 0.022  4.94 (1.83 - 13.32) 0.002 
Loss of autonomy for at least 2 activities     
 No 1.00   1.00  
 yes 1.71 (0.86 - 3.40) 0.124  0.72 (0.26 - 2.01) 0.529 
Loss  >= 3 points on MMSE in the previous year     
 No      1.00  
 yes      2.81 (1.03 - 7.65) 0.043 
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Table 4. Association between baseline characteristics of patients and the Deco score 
    m sd p-value 
Sex         
 
Male 18,5 9,1 0,618 
 
Female 19,2 8,7 
 Age 
    
 
<75 years old 19,1 8,8 0,803 
 
>= 75 years old 18,8 8,9 
 Residential status 
   
 
Out-patients 18,8 8,8 0,727 
 
Institution 19,6 9,6 
 Level of education 
   
 
Primary or short secondary school 19,1 9,1 0,388 
 
long secondary school 18,3 8,1 
 Loss of autonomy for at least 2 activities 
  
 
No 20,3 8,6 0,071 
 
yes 17,9 8,9 
 Rapid decline between inclusion and 12-month visit 
 
 
No 20,2 8,9 0,0008 
  yes 15,1 7,4   
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Table 5. Predictive power of 3 thresholds of the Deco score. Univariate logistic regression. 
  RCD             
  Yes No OR (95%I.C.) p-value Se Sp PPV NPV 
DECO > 16 17 (37.8) 85 (64.4)      1.00           
DECO <= 16 28 (62.2) 47 (35.6) 2.98 (1.46-6.00) 0.002 62.2 64.4 37.3 83.3 
         
DECO > 17 16 (35.6) 79 (64.4)      1.00      
DECO <= 17 29 (59.9) 53 (40.2) 2.70 (1.34-5.46) 0.006 64.4 59.9 35.4 83.2 
         
DECO > 18 15 (33.3) 72 (54.6)      1.00      
DECO <= 18 30 (66.7) 60 (45.5) 2.40 (1.18-4.87) 0.015 66.7 54.6 33.3 82.8 
RCD states for rapid cognitive decline, Se for sensitivity, Sp for specificity, PPV for positive 
predictive value, NPV for negative predictive value 
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Table 6. Best predictive thresholds of the Deco score according to age-groups. Univariate 
logistic regression. 
 
  RCD       
  Yes No OR (95%I.C.) p-value Se Sp VPP VPN 
Age < 75 yrs old           
 DECO > 16 4 (26.7) 29 (70.7) 1.00      
 DECO <= 16 11 (73.3) 12 (29.3) 6.65 (1.76-25.1) 0.005 73.3 70.7 47.8 87.9 
Age >= 75 yrs old         
 DECO > 14 14 (17.5) 66 (82.5) 1.00      
  DECO <= 14 16 (39.0) 25 (61.0) 3.02 (1.29-7.08) 0.011 57.8 74.2 43.3 83.8 
RCD states for rapid cognitive decline, Se for sensitivity, Sp for specificity, PPV for positive 
predictive value, NPV for negative predictive value 
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Neurologists
contacted
350
Actives neurologists
152
150 Refused participation
48 Accepted participation        
but did not include patients
Patients included
361
85 No data after inclusion
6 Missing data on MMSE
Patients followed-up              
at least once
270
Lost to follow-up 
before 12-month visit
Patients included
in the per-protocol
analysis
204
66
 
Figure 1: Flow chart of the patients‟ selection for the per-protocol analysis 
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Figure 2: ROC curve for the prediction of rapid cognitive decline according to DECO scores 
 
 
